CU23740A1 - Método de obtención de una formulación de antígenos del virus de la hepatitis b - Google Patents
Método de obtención de una formulación de antígenos del virus de la hepatitis bInfo
- Publication number
- CU23740A1 CU23740A1 CU20090164A CU20090164A CU23740A1 CU 23740 A1 CU23740 A1 CU 23740A1 CU 20090164 A CU20090164 A CU 20090164A CU 20090164 A CU20090164 A CU 20090164A CU 23740 A1 CU23740 A1 CU 23740A1
- Authority
- CU
- Cuba
- Prior art keywords
- formulation
- antigens
- hbv
- cells
- stimulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con el campo de la inmunización terapéutica, específicamente con el empleo de una nueva formulación de antígenos del virus de la Hepatitis B (VHB) para la estimulación celular. La formulación está formada por precipitados en suspensión de los antígenos de la superficie (HBsAg) y de la nucleocápsida (HBcAg) del VHB. La formulación contiene a dichos antígenos como precipitados en suspensión de partículas de tallas inferiores a 500 nm y superiores a 500nm, en una mezcla donde la proporción entre las partículas de las tallas mencionadas está entre 50%-50% y 80%-20%, respectivamente. La selección de un rango de tallas de partículas permite que los niveles de estimulación de varios tipos celulares sea el máximo. Adicionalmente, se describe3 un método de estimulación celular con dicha formulación, y la posterior inmunización pasiva de pacientes con Hepatitis B crónica, basado en la máxima estimulación in vivo o in vitro de células heterólogas o autólogas (células dendríticas, células B y macrófagos). Las células estimuladas con esta formulación se transfieren a pacientes infectados crónicamente con el VHB.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090164A CU23740A1 (es) | 2009-09-29 | 2009-09-29 | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
| KR1020127008797A KR20120080598A (ko) | 2009-09-29 | 2010-09-28 | 치료적 면역화반응이 따르는 세포 자극용 비형 간염 바이러스 항원의 제형 |
| RU2012117233/10A RU2012117233A (ru) | 2009-09-29 | 2010-09-28 | Состав антигенов вируса гепатита в для клеточной стимуляции с последующей терапевтической иммунизацией |
| PCT/CU2010/000003 WO2011038701A1 (es) | 2009-09-29 | 2010-09-28 | Formulación de antigenos del virus de la hepatitis b para la estimulación celular seguida de la inmunización terapéutica |
| CN2010800489910A CN102665687A (zh) | 2009-09-29 | 2010-09-28 | 用于细胞刺激随后进行治疗性免疫的乙肝病毒抗原制剂 |
| EP10770699A EP2484343A1 (en) | 2009-09-29 | 2010-09-28 | Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization |
| US13/498,842 US20120308615A1 (en) | 2009-09-29 | 2010-09-28 | Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization |
| BR112012007180A BR112012007180A2 (pt) | 2009-09-29 | 2010-09-28 | formulação dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b, métodos de obtenção de uma formulação dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b, de estimulação de células para a imunoterapia passiva e de imunização passiva de pacientes com hepatite b crônica e uso de uma formulação composta por precipitados em suspensão dos antígenos da superfície e do nucleocapsídio do vírus da hepatite b |
| CA2775794A CA2775794A1 (en) | 2009-09-29 | 2010-09-28 | Formulation of hepatitis b virus antigens for cellular stimulation followed by therapeutic immunization |
| AU2010302740A AU2010302740A1 (en) | 2009-09-29 | 2010-09-28 | Hepatitis B virus antigen formulation for cell stimulation followed by therapeutic immunization |
| JP2012531233A JP2013505971A (ja) | 2009-09-29 | 2010-09-28 | 治療上の免疫化後の細胞性刺激のためのb型肝炎ウイルス抗原製剤 |
| ZA2012/02768A ZA201202768B (en) | 2009-09-29 | 2012-04-16 | Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090164A CU23740A1 (es) | 2009-09-29 | 2009-09-29 | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23740A1 true CU23740A1 (es) | 2011-12-28 |
Family
ID=43127828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20090164A CU23740A1 (es) | 2009-09-29 | 2009-09-29 | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120308615A1 (es) |
| EP (1) | EP2484343A1 (es) |
| JP (1) | JP2013505971A (es) |
| KR (1) | KR20120080598A (es) |
| CN (1) | CN102665687A (es) |
| AU (1) | AU2010302740A1 (es) |
| BR (1) | BR112012007180A2 (es) |
| CA (1) | CA2775794A1 (es) |
| CU (1) | CU23740A1 (es) |
| RU (1) | RU2012117233A (es) |
| WO (1) | WO2011038701A1 (es) |
| ZA (1) | ZA201202768B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104043120B (zh) * | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | 乙型肝炎疫苗 |
| EP3437654B1 (en) * | 2016-03-31 | 2023-09-20 | Centro De Ingeniería Genética Y Biotecnología | Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus |
| CN111450245A (zh) * | 2020-04-29 | 2020-07-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种乙型肝炎治疗疫苗及其制备方法 |
| WO2025140549A1 (en) * | 2023-12-29 | 2025-07-03 | Etinpro (Beijing) Co. Ltd. | Immune stimulating anti-hbsag antibody conjugates, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22290A1 (es) | 1990-10-08 | 1995-01-31 | Cigb | Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal |
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| US20010053365A1 (en) * | 1995-04-25 | 2001-12-20 | Smithkline Beecham Biologicals S.A. | Vaccines |
| ATE229810T1 (de) * | 1996-10-11 | 2003-01-15 | Univ California | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
| CU23002A1 (es) * | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| CU23405A1 (es) * | 2003-10-20 | 2009-08-04 | Ct Ingenieria Genetica Biotech | Composiciones farmacéuticas para uso terapéutico |
| CN1919341B (zh) * | 2005-08-24 | 2012-01-25 | 复旦大学 | 乙肝表面抗原-抗体复合物在制备对乙肝疫苗无应答或低应答预防制品中的用途 |
| CN1981866B (zh) * | 2006-04-30 | 2011-04-06 | 解放军三○二医院生物治疗研究中心 | 新型慢性乙肝治疗性dc疫苗 |
| WO2008104133A1 (es) * | 2007-02-28 | 2008-09-04 | Centro De Ingeniería Genética Y Biotecnología | Terapia combinada para el tratamiento de la hepatitis b crónica |
| US8877208B2 (en) * | 2008-05-23 | 2014-11-04 | The Regents Of The University Of Michigan | Multivalent nanoemulsion vaccines |
-
2009
- 2009-09-29 CU CU20090164A patent/CU23740A1/es not_active IP Right Cessation
-
2010
- 2010-09-28 JP JP2012531233A patent/JP2013505971A/ja active Pending
- 2010-09-28 CA CA2775794A patent/CA2775794A1/en not_active Abandoned
- 2010-09-28 EP EP10770699A patent/EP2484343A1/en not_active Withdrawn
- 2010-09-28 RU RU2012117233/10A patent/RU2012117233A/ru not_active Application Discontinuation
- 2010-09-28 WO PCT/CU2010/000003 patent/WO2011038701A1/es not_active Ceased
- 2010-09-28 AU AU2010302740A patent/AU2010302740A1/en not_active Abandoned
- 2010-09-28 CN CN2010800489910A patent/CN102665687A/zh active Pending
- 2010-09-28 KR KR1020127008797A patent/KR20120080598A/ko not_active Withdrawn
- 2010-09-28 BR BR112012007180A patent/BR112012007180A2/pt not_active Application Discontinuation
- 2010-09-28 US US13/498,842 patent/US20120308615A1/en not_active Abandoned
-
2012
- 2012-04-16 ZA ZA2012/02768A patent/ZA201202768B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012007180A2 (pt) | 2016-03-29 |
| EP2484343A1 (en) | 2012-08-08 |
| CA2775794A1 (en) | 2011-04-07 |
| JP2013505971A (ja) | 2013-02-21 |
| WO2011038701A1 (es) | 2011-04-07 |
| US20120308615A1 (en) | 2012-12-06 |
| KR20120080598A (ko) | 2012-07-17 |
| CN102665687A (zh) | 2012-09-12 |
| RU2012117233A (ru) | 2013-11-10 |
| ZA201202768B (en) | 2012-12-27 |
| AU2010302740A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087380A1 (es) | Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas | |
| NZ592977A (en) | IgE CH3 PEPTIDE VACCINE | |
| CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
| CL2021001195A1 (es) | Agentes de iarn para infección causada por el virus de la hepatitis b. (divisional de solicitud 201900278) | |
| UY37998A (es) | Agentes antivirales contra la hepatitis b | |
| CO6571891A2 (es) | Inhibidores del virus de la hepatitis c. | |
| UY37997A (es) | Agentes antivirales contra la hepatitis b | |
| UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
| CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
| ECSP14005678A (es) | Composiciones y métodos para tratar el virus de la hepatitis c | |
| CO6592102A2 (es) | Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
| WO2015061294A8 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
| EA201270173A1 (ru) | Получение полиовируса с высокими титрами для получения вакцины | |
| AR074487A1 (es) | Tiolactamas inhibidoras de proteinquinasas plk, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de trastornos proliferativos e inflamatorios, en particular cancer. | |
| NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CY1117964T1 (el) | Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας | |
| NZ742005A (en) | Pharmaceutical nanoparticles showing improved mucosal transport | |
| AR081859A1 (es) | Pirimidinas 2,4,6-trisustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de tumores sensibles a la inhibicion de la cinasa atr | |
| BR112012009962A2 (pt) | método para a proliferação de células tantígeno específicas. | |
| UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
| MX387420B (es) | Producción de virus en cultivos celulares. | |
| AR079890A1 (es) | Estabilizacion de peliculas de oxido de zinc en composiciones bucales | |
| MX2014010482A (es) | Metodo para la preparacion de vacunas de celulas dendriticas. | |
| EP2570519A3 (en) | Localized, In-Vacuum Modification of Small Structures | |
| JP2014512391A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent | ||
| FD | Lapse (for not paying fees) |